Relative bioavailability of tizanidine 4-mg capsule and tablet formulations after a standardized high-fat meal: A single-dose, randomized, open-label, crossover study in healthy subjects

Clinical Therapeutics

Volumn 29, Issue 4, 2007, Pages 661-669

  Henney III, Herbert R ^a   Shah, Jaymin ^b  

^a ACORDA THERAPEUTICS INC   (United States)

^b ELAN PHARMACEUTICALS   (United States)

Author keywords

bioavailability; formulation; pharmacokinetics; tizanidine

Indexed keywords

TIZANIDINE;

ADULT; ARTICLE; ASTHENIA; BIOAVAILABILITY; BIOEQUIVALENCE; BLOOD ANALYSIS; BLOOD SAMPLING; CAPSULE ENDOSCOPE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIZZINESS; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG TOLERABILITY; ELECTROCARDIOGRAPHY; FEMALE; HEADACHE; HUMAN; HUMAN EXPERIMENT; LIPID DIET; MALE; MAXIMUM PLASMA CONCENTRATION; MYALGIA; NORMAL HUMAN; PHYSICAL EXAMINATION; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SOMNOLENCE; SPASTICITY; STANDARDIZATION; TABLET; TASTE DISORDER; TIME TO MAXIMUM PLASMA CONCENTRATION; URINALYSIS; VITAL SIGN; XEROSTOMIA;

ADULT; ASTHENIA; BIOLOGICAL AVAILABILITY; CAPSULES; CLONIDINE; CROSS-OVER STUDIES; DIETARY FATS; DOSAGE FORMS; FEMALE; FOOD-DRUG INTERACTIONS; HUMANS; MALE; MUSCLE RELAXANTS, CENTRAL; TABLETS;

EID: 34347351154     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2007.04.012     Document Type: Article

References (24)

1. Zanaflex (tizanidine hydrochloride) [prescribing information] (2006), Acorda Therapeutics, Inc, Hawthorne, NY
2. Wagstaff A.J., and Bryson H.M. Tizanidine. A review of its pharmacology, clinical efficacy and tolerability in the management of spasticity associated with cerebral and spinal disorders. Drugs 53 (1997) 435-452
3. Davies J. Selective depression of synaptic transmission of spinal neurones in the cat by a new centrally acting muscle relaxant, 5-chloro-4-(2-imidazolin-2-yl-amino)-2,1,3 benzothiodazole (DS103-282). Br J Pharmacol. 76 (1982) 473-481
4. Palmeri A., and Wiesendanger M. Concomitant depression of locus coeruleus neurons and of flexor reflexes by an alpha 2-adrenergic agonist in rats: A possible mechanism for an alpha 2-mediated muscle relaxation. Neuroscience 34 (1990) 177-187
5. Tse F.L., Jaffe J.M., and Bhuta S. Pharmacokinetics of orally administered tizanidine in healthy volunteers. Fundam Clin Pharmacol 1 (1987) 479-488
6. Shah J., Wesnes K.A., Kovelesky R.A., and Henney III H.R. Effects of food on the single-dose pharmacokinetics/pharmacodynamics of tizanidine capsules and tablets in healthy volunteers. Clin Ther. 28 (2006) 1308-1317
7. Mathias C.J., Luckitt J., Desai P., et al. Pharmacodynamics and pharmacokinetics of the oral antispastic agent tizanidine in patients with spinal cord injury. J Rehabil Res Dev. 26 (1989) 9-16
8. Emre M., Leslie G.C., Muir C., et al. Correlations between dose, plasma concentrations, and antispastic action of tizanidine (Sirdalud). J Neurol Neurosurg Psychiatry. 57 (1994) 1355-1359
9. Roberts R.C., Part N.J., Pokorny R., et al. Pharmacokinetics and pharmacodynamics of tizanidine. Neurology 44 Suppl 9 (1994) S29-S31
10. Granfors M.T., Backman J.T., Laitila J., and Neuvonen P.J. Tizanidine is mainly metabolized by cytochrome P450 1A2 in vitro. Br J Clin Pharmacol. 57 (2004) 349-353
11. Granfors M.T., Backman J.T., Neuvonen M., et al. Fluvoxamine drastically increases concentrations and effects of tizanidine: A potentially hazardous interaction. Clin Pharmacol Ther. 75 (2004) 331-341
12. Granfors M.T., Backman J.T., Neuvonen M., and Neuvonen P.J. Ciprofloxacin greatly increases concentrations and hypotensive effect of tizanidine by inhibiting its cytochrome P450 1A2mediated presystemic metabolism. Clin Pharmacol Ther. 76 (2004) 598-606
13. Granfors M.T., Backman J.T., Laitila J., and Neuvonen P.J. Oral contraceptives containing ethinyl estradiol and gestodene markedly increase plasma concentrations and effects of tizanidine by inhibiting cytochrome P450 1A2. Clin Pharmacol Ther. 78 (2005) 400-411
14. Nance P.W., Sheremata W.A., Lynch S.G., et al. Relationship of the antispasticity effect of tizanidine to plasma concentration in patients with multiple sclerosis. Arch Neurol. 54 (1997) 731-736
15. Ashworth B. Preliminary trial of carisoprodol in multiple sclerosis. Practitioner 192 (1964) 540-542
16. Wartenburg R. Pendulousness of the legs as a diagnostic test. Neurology 1 (1951) 18-24
17. Wechsler D. WechslerAdult Intelligence Scale. Manual (1955), Psychological Corporation, New York, NY
18. European Agency for the Evaluation of Medicinal Products, International Conference on Harmonisation World Health Organization. Guideline for Good Clinical Practice [EMEA Web site]. ICH Topic E6 (2002-2007), WHO, Geneva, Switzerland. http://www.emea.eu.int
19. World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects [WMA Web site]. Adopted by the 18th WMA General Assembly. Helsinki, Finland, June 1964 (2007). http://www.wma.net/e/policy/63.htm
20. 1983 Metropolitan height and weight tables. Anonymous. Stat Bull Metrop Life Found. 64 (1983) 3-9
21. Guidance for Industry. Bioavailability and bioequivalence studies for orally administered drug products general considerations (2003), US Food and Drug Administration, Center for Drug Evaluation and Research, Bethesda, Md
22. Guidance for Industry. Statistical approaches to establishing bioequivalence (2001), US Food and Drug Administration, Center for Drug Evaluation and Research, Bethesda, Md
23. Biostudy 300003 (2000), Acorda Therapeutics, Hawthorne, NY
24. Taittonen M., Raty H., Kirvela O., et al. The metabolic effects of oral tizanidine in healthy volunteers. Acta Anaesthesiol Scand. 39 (1995) 628-632